Almac Makes Further significant Co-Investment to Meet Japanese Client Demand for Humidity Controlled Blister Packaging
Almac has expanded its UK commercial packaging facility, with a significant investment, to provide a state-of-the-art humidity controlled blister packaging suite, complete with off-line “just in time” blister printing.
Meeting the requirements of two Japanese clients, the expansion included extensive suite modifications for processing humidity sensitive drug products; installation of a new Noack 623 blister line, a custom designed desiccant feeder and an off-line Hapa Blister-Jet printer.
The Noack blister line provides enhanced flexibility for processing larger blister sizes and innovative multi-product blister formats; it can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220 mm x 155 mm. This versatile line facilitated the integration of a bespoke desiccant feeder that cuts, picks and places reel-fed desiccant wafers into blister pockets.
The off-line Hapa Blister-Jet augments just-in-time production. By printing country-specific artwork and variable data on each individual blister pocket, it enhances flexibility and significantly reduces stock holding.
James MacKenzie, Commercial Director at Hapa notes: “Almac represents an exciting watermark for Hapa. This partnership indicates that our innovation strategy — with high investment in just-in-time, on demand print technologies is on the right track. As order sizes continue to fall, the business case for late stage customisation continues to grow. The addition of the Blister-Jet to Almac’s portfolio extends their capability to provide rapid and efficient late stage customisation of bulk-packed blisters.” He explained that Almac’s partnership-approach to working with clients is shared by Hapa. “Their expertise,”MacKenzie added, “enables us to deliver this project quickly and efficiently.”
David Downey, Almac’s VP of Commercial Operations explains: “This co-investment allows Almac to address complex packaging challenges associated with innovative drug products that require enhanced environmental controls but, importantly, also provides our partners with the option to address modest country-specific market volumes, by off-line printing blank blisters through the Hapa unit. This solution will be of significant value to those companies launching orphan and niche blistered drug products into EU and ROW markets, many of which Almac already support.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.